Engineered tissue-resident natural killer cells slow solid tumour growth in mouse models

A study reported by ScienceDaily on 25 August 2026 describes a laboratory approach to enhancing natural killer (NK) cells — innate immune cells with intrinsic anti-tumour activity — so that they can penetrate and sustain activity within solid tumours, an environment that typically suppresses immune cell function.

The researchers prepared tissue-resident NK cells using an undisclosed conditioning approach and tested them in mouse models of melanoma and head and neck cancers. In those models, the engineered cells slowed tumour growth. A combination with cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is already used clinically in certain head and neck and colorectal cancers, produced a stronger effect than either intervention alone in the preclinical setting.

The work is at an early, animal-model stage. The full author list, institution, and journal were not specified in the available feed text; readers working in translational oncology or immunotherapy research should consult the primary publication for methodological detail, including how the tissue-resident phenotype was induced and maintained. No human trial data are described in the reported findings.